View in EDS

Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.

Saved in:
Bibliographic Details
Title: Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Authors: Boutry, Céline1, Hastie, Andrew2 andrew.x.hastie@gsk.com, Diez-Domingo, Javier3, Tinoco, Juan Carlos4, Yu, Chong-Jen5, Andrews, Charles6, Beytout, Jean7, Caso, Covadonga8, Cheng, Huey-Shinn9, Cheong, Hee Jin10, Choo, Eun Ju11, Curiac, Dan12, Paolo, Emmanuel Di13, Dionne, Marc14, Eckermann, Tamara15, Esen, Meral16, Ferguson, Murdo17, Ghesquiere, Wayne18, Hwang, Shinn-Jang19,20, Avelino-Silva, Thiago Junqueira21
Source: Clinical Infectious Diseases. 4/15/2022, Vol. 74 Issue 8, p1459-1467. 9p.
Database: Environment Complete
Description
ISSN:10584838
DOI:10.1093/cid/ciab629